C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy (Q42786749)

7 November 2017

C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy (English)

1 reference

Fluorodeoxyglucose Positron Emission Tomography

7 November 2017

1 reference

1 reference

7

Celestia S Higano

1 reference

7 November 2017

Evan Y Yu

1

1 reference

7 November 2017

Mark Muzi

2

1 reference

7 November 2017

Joy A Hackenbracht

3

1 reference

7 November 2017

Brian B Rezvani

4

1 reference

7 November 2017

Jeanne M Link

5

1 reference

7 November 2017

Robert Bruce Montgomery

6

1 reference

7 November 2017

Janet F Eary

8

1 reference

7 November 2017

David A Mankoff

9

1 reference

7 November 2017

1 March 2011

1 reference

Clinical Nuclear Medicine

7 November 2017

1 reference

7 November 2017

36

1 reference

7 November 2017

3

1 reference

7 November 2017

192-198

1 reference

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

27 May 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Positron emission tomography for prostate, bladder, and renal cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

11C-acetate PET imaging of prostate cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3129631

Selective activation of the fatty acid synthesis pathway in human prostate cancer

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285676

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Preparation of [1-11C]acetate--an agent for the study of myocardial metabolism by positron emission tomography

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285676

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285676

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/RLU.0B013E318208F140

1 reference

7 November 2017

1 reference

7 November 2017

PubMed publication ID

21285676

1 reference